Mizuho Securities analyst Difei Yang maintained a Hold rating on Marinus (MRNS) today and set a price target of $5. The company’s shares closed yesterday at $3.94.
Yang commented:
“We expect these two readouts will be key catalysts for MRNS shares. Data from a proof-of-concept study in refractory status epilepticus (RSE) could also be available in 2Q19.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 19.1% and a 50.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Marinus has an analyst consensus of Strong Buy, with a price target consensus of $17.17.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.54 and a one-year low of $2.36. Currently, Marinus has an average volume of 1.11M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
